James Lovett

BIG NEWS! Genezen has signed an agreement to acquire uniQure’s commercial gene therapy manufacturing operations in Lexington, Massachusetts. This strategic acquisition will enable Genezen to deliver late-phase and commercial gene therapy development and manufacturing services to customers around the world. Steve Favaloro, President and Chief Executive Officer of Genezen, commented, “...This acquisition significantly enhances Genezen’s scale and differentiated capabilities, directly aligned with our mission to advance cell and gene therapies by providing top-tier, science-driven development and manufacturing solutions. We are honored to deliver these services to our current customers and the patients they serve, and are well positioned to immediately extend our support to even more customers in Lexington.” #cdmo #viralvectors #cellandgenetherapy #celltherapy #genetherapy #precisionmedicine #mergersandacquisitions #investment #finance #pharma #biotech CSL Ampersand Capital Partners https://lnkd.in/eqDDc_cf

194

15 Comments

Yesterday, Gordon Haner, MBA, LATG, ILAM was onsite at EMD Serono, Inc. for a Biotech Vendor Services, Inc. vendor show! Thank you to all those who came to talk to Gordon about GemPharmatech's mouse models and preclinical services. If you are in the #bostonbiotech community make sure to reach our to Gordon if you do preclinical research with mouse models. Also a thank you to Matthew Potter and BVS! See you again soon, new EMD and MilliporeSigma friends! #preclinicalresearch #oncology #autoimmune #vendorshow #bvs #bvsvendorshow

29

The Chamber of Commerce for Greater Philadelphia released “Leading the Way: Cell and Gene Therapy in Greater Philadelphia Sector Snapshot 2024." This in-depth report describes the Greater Philadelphia region’s remarkable growth journey in the cell and gene therapy (CGT) sector over the past decade, showcases how Greater Philadelphia has emerged as a global leader in CGT and highlights a variety of Penn’s contributions to the field. The report notes that Penn has spun out 40 companies since 2018, which has significantly contributed to the growth of the CGT sector in Greater Philadelphia. In addition, Penn Medicine was recognized as a top location for Phase I and II trials in novel cell and gene therapies and the Penn mRNA Institute recently received a $350 million investment. All of this has helped further grow the expanding CGT space in Philadelphia, which has received over $8 billion in private capital invested since 2018 and generated 7,000 jobs. Read the full report here: https://lnkd.in/g-UKX6Rc 

21

In the latest edition, Most Visionary People Transforming Pharma and Life Sciences, CIOLOOK Magazine is pleased to feature #OmerSeyan, Chief Executive Officer of Hawkary Pharmaceuticals Co., along with other dynamic visionary leaders. Read More: https://cutt.ly/dey2nxut #pharmaceutical #pharmaceuticalindustry #pharmaceuticalmanufacturing #pharmaindustry #healthcare #businessmagazine #ciolook

1

NImmune Biopharma, Inc’s Founder, Executive Chairman & CEO Josep B. was recently honored as a Virginia Success Story at THRiVE, Virginia Bio’s largest conference of the year. Dr. Bassaganya-Riera described his role in building a thriving biotech innovation ecosystem from the ground up, encompassing NImmune Biopharma, The NIMML Institute, and BioTherapeutics Inc., alongside Landos Biopharma, Inc., which was recently acquired by AbbVie. He underscored the groundbreaking potential of NImmune’s therapeutics in addressing the unmet clinical needs of millions of patients suffering from autoimmune diseases worldwide. NImmune’s lead drug, omilancor, is a first-in-class, best-in-class, oral, once-daily therapeutic in Phase 3 clinical development with a planned NDA filing for Ulcerative Colitis by 2026 and in Phase 2 clinical development for Crohn’s disease. Additionally, NIM-1324, a first-in-class, oral, once-daily, systemically distributed LANCL2 agonist, is in Phase 2 clinical development for the treatment of systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis and other undisclosed indications. Watch Dr. Bassaganya-Riera’s full remarks below.   #VirginiaBio #THRiVE #PrecisionMedicine #LANCL2

25

3 Comments

Will you be at #BioprocessingSummit in #Boston this week? If so, don't forget to stop by Booth 326 and chat with our experts about your bioprocessing needs! You've got questions, we've got answers 👍 #CHIBioprocessingSummit #Lifesciences

16

How do you ensure your projects align with your organization's strategic vision? 🌐 Learn from Danette Astolfi, Senior Director of Project Management at Elevar Therapeutics, at our Boston conference. She'll discuss aligning projects and programs with business goals, sharing strategies from a leading pharmaceutical company. What challenges are you facing in strategic alignment? Let's find solutions together—reserve your seat today! https://lnkd.in/dmKigmrk #PPM #Boston #PharmaConference #StrategicAlignment

10